Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.
| Condition | Intervention |
|---|---|
|
Thyroid Cancer |
Drug: Iodine-124 Drug: Iodine-123 Drug: F-18 FDG |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection |
| Estimated Enrollment: | 100 |
| Study Start Date: | May 2007 |
-
Drug: Iodine-124
- Fludeoxyglucose (18 F)
- fluorodeoxyglucose (18 F)
- MIPS
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.
Conducting this study we hope to find whether I-124 PET/CT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PET/CT.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Participants with Thyroid cancer
Inclusion Criteria:- Patient at Nuclear Medicine clinic at Stanford University Medical Center
- Treated thyroid cancer.
- Detectable levels of Tg.
- Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.
- Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT
- Patients older than 18-year-old.
- Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.
- Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.
- Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.
Exclusion Criteria:- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.
- Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.
- Pregnant women.
- Healthy volunteers.
- Patients participating in other research studies.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Iain Ross McDougall, Stanford University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT00373711 History of Changes |
| Other Study ID Numbers: | END0003, 97454, END0003 |
| Study First Received: | September 6, 2006 |
| Last Updated: | April 7, 2011 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Thyroid Neoplasms Thyroid Diseases Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Head and Neck Neoplasms Endocrine System Diseases Iodine Cadexomer iodine |
Anti-Infective Agents, Local Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Trace Elements Micronutrients Growth Substances Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013